Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients.

Autor: Liu M; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Wang S; The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Liang Y; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Fan Y; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China., Wang W; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China. jack1987168@163.com.
Jazyk: angličtina
Zdroj: Clinical rheumatology [Clin Rheumatol] 2024 Aug; Vol. 43 (8), pp. 2403-2416. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1007/s10067-024-07046-8
Abstrakt: Systemic lupus erythematosus (SLE) is a common autoimmune disease with a polymorphic clinical presentation involving multisystem damages with significant differences in prevalence and disease severity among different ethnic groups. Although genetic, hormonal, and environmental factors have been demonstrated to contribute a lot to SLE, the pathogenesis of SLE is still unknown. Numerous evidence revealed that gene variants within the type I interferons (IFN) signaling pathway performed the great genetic associations with autoimmune diseases including SLE. To date, through genome-wide association studies (GWAS), genetic association studies showed that more than 100 susceptibility genes have been linked to the pathogenesis of SLE, among which TYK2, STAT1, STAT4, and IRF5 are important molecules directly connected to the type I interferon signaling system. The review summarized the genetic associations and the detailed risk loci of STAT4 and IRF5 with Asian SLE patients, explored the genotype distributions associated with the main clinical manifestations of SLE, and sorted out the potential reasons for the differences in susceptibility in Asia and Europe. Moreover, the therapies targeting STAT4 and IRF5 were also evaluated in order to propose more personalized and targeted treatment plans in SLE.
(© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).)
Databáze: MEDLINE
Externí odkaz: